Skip to content

Targeted Lidocaine Infusion for Pain Reduction in Office Hysteroscopy

A Modified Technique of Target Lidocaine Infusion for Pain Control in Office Hysteroscopy: A Double-Blind Randomized Controlled

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07318285
Acronym
OPTILID
Enrollment
208
Registered
2026-01-05
Start date
2026-02-01
Completion date
2029-12-30
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopy / Methods, Lidocaine Infusion, Placebo - Control

Brief summary

The goal of this study is to find out whether a small amount of lidocaine (a common local anesthetic) can reduce pain during office hysteroscopy - a procedure used to look inside the uterus. The study will compare lidocaine to saline (salt water) to see which one helps more with pain relief. Participants will: 1. Receive either lidocaine or saline gently applied inside the cervix right before the procedure 2. Undergo the hysteroscopy as planned 3. Be asked to rate their pain and satisfaction after the procedure Lidocaine is commonly and safely used in dental and gynecological procedures. Participation is voluntary, and the procedure itself will not change.

Interventions

A 5 mL dose of 2% lidocaine solution will be infused slowly through the internal os using the hysteroscope before the start of uterine cavity distension.

OTHERSaline (0.9% NaCl)

A 5 mL dose of sterile normal saline will be infused slowly through the internal os using the same technique as in the intervention arm, immediately before cavity distension.

Sponsors

YAARA TABIB
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * Referred for outpatient diagnostic or operative (see-and-treat) hysteroscopy * Able and willing to provide written informed consent

Exclusion criteria

* Pregnancy * Active pelvic inflammatory disease or cervicitis * Inability to consent * Anti-psychotic drugs usage * Previews cervical surgery (i.e., conization). * Any contraindication for office hysteroscopy- cervical malignancy, profuse uterine bleeding, invisible external os, recent uterine perforation. * Known allergy or hypersensitivity to Lidocaine

Design outcomes

Primary

MeasureTime frameDescription
Pain During Hysteroscopy Procedure Assessed by Visual Analog Scale (VAS)Immediately during the hysteroscopy procedurePain experienced during the procedure, evaluated using a Visual Analog Scale (VAS). The VAS score ranging between 0 (no pain) to 10 (worst imaginable pain). Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.
Number of Participants with Successful Access to the Uterine CavityDuring the hysteroscopy procedureThe number of participants for whom hysteroscopy successfully reached the uterine cavity, without the need to stop or repeat the procedure. This binary outcome (Yes/No) will be assessed by the performing physician during the procedure. Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.

Secondary

MeasureTime frameDescription
Completed procedureDuring the hysteroscopy procedureSuccessful performance of the intended hysteroscopic procedure. Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.
Visual Analog Scale (VAS) Pain Score 5 Minutes After the Procedure5 minutes after completion of the hysteroscopy procedurePain intensity assessed using a Visual Analog Scale (VAS) exactly 5 minutes following the end of the hysteroscopy. The VAS score ranging between 0 (no pain) to 10 (worst imaginable pain). Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.
Adverse effectDuring and up to 10 minutes after the procedureRecording any vasovagal symptoms observed or reported, including nausea, bradycardia, or hypotension.
Patient satisfactionImmediately after the procedurePatient-reported satisfaction with the procedure using a validated 5-point Likert scale. Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.
Change in Visual Analog Scale (VAS) Pain Score from Baseline to During the ProcedureChanges of VAS score of pain from baseline (before procedure) and at 5 minutes of during procedure.The outcome will measure the change in pain score using the Visual Analog Scale (VAS) from baseline (immediately before the hysteroscopy) to during the procedure. The VAS score ranging between 0 (no pain) to 10 (worst imaginable pain). Subgroup analyses will be performed by age group, parity, cesarean delivery history, and menopausal status.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026